Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

Background: An earlier analysis of the PEARL phase III study showed that palbociclib plus endocrine therapy (ET) does not improve progression-free survival (PFS) over capecitabine in aromatase inhibitor-resistant, hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic...

Full description

Bibliographic Details
Main Authors: Alba, E. (Author), Alonso-Romero, J.L (Author), Antón, A. (Author), Bermejo, B. (Author), Calvo, L. (Author), Carrasco, E. (Author), Casas, M.I (Author), Ciruelos, E.M (Author), Corsaro, M. (Author), Csöszi, T. (Author), de la Haba-Rodríguez, J. (Author), Gil-Gil, M. (Author), Huang, X. (Author), Kahan, Z. (Author), Margelí, M. (Author), Martín, M. (Author), Morales, S. (Author), Muñoz, M. (Author), Murillo, L. (Author), Ramos, M. (Author), Ruiz-Borrego, M. (Author), Sánchez-Rovira, P. (Author), Santaballa, A. (Author), Thallinger, C. (Author), Turner, N. (Author), Zielinski, C. (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
Capecitabine
CDK4/6 inhibitor
Endocrine therapy
HER2–negative
Hormone receptor-positive metastatic breast cancer
Overall survival
Palbociclib
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items